CORRECTION:Jefferies analyst Kelly Shi initiates coverage on CTI BioPharma (NASDAQ:CTIC) with a Buy rating and announces Price Target of $13, correct Analyst Firm updated.
Ford Motor Co (NYSE: F) and Volkswagen AG’s (OTC: VWAGY) battery supplier SK Innovation Co said on Wednesday it is splitting the battery business amid rising global demand for electric vehicles.